OSE Immunotherapeutics SA (EPA: OSE)
France
· Delayed Price · Currency is EUR 7.06
-0.05 (-0.70%)
Dec 20, 2024, 5:35 PM CET
OSE Immunotherapeutics Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 46.03 | -23 | -17.76 | -16.85 | -16.56 | -4.65 | Upgrade
|
| Depreciation & Amortization | -0.14 | 1.17 | 3.54 | 2.66 | 0.73 | 0.48 | Upgrade
|
| Other Amortization | 3.53 | 2.36 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 1.31 | 1.75 | 2.73 | 2.94 | 1.79 | 1.51 | Upgrade
|
| Other Operating Activities | -0.13 | -0.98 | -3.38 | 0.64 | -2.32 | 3.24 | Upgrade
|
| Change in Income Taxes | 3.41 | -0.22 | -0.24 | -0.33 | - | - | Upgrade
|
| Change in Other Net Operating Assets | 8.49 | -0.84 | -3.14 | 1.03 | -3.19 | 8.56 | Upgrade
|
| Operating Cash Flow | 58.36 | -19.76 | -18.25 | -9.92 | -19.55 | 9.14 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | - | 748.19% | Upgrade
|
| Capital Expenditures | -0.03 | -0.02 | -0.27 | -0.47 | -0.21 | -0.34 | Upgrade
|
| Investment in Securities | -54.94 | 0 | - | - | - | 2.9 | Upgrade
|
| Other Investing Activities | -0.54 | -0.49 | 0.3 | -0.36 | -0.29 | -0.18 | Upgrade
|
| Investing Cash Flow | -55.53 | -0.51 | 0.03 | -0.83 | -0.5 | 2.38 | Upgrade
|
| Long-Term Debt Issued | - | 5.02 | 12.06 | 15.28 | 6.96 | 5.63 | Upgrade
|
| Long-Term Debt Repaid | - | -3.36 | -1.8 | -0.59 | -0.81 | -0.71 | Upgrade
|
| Net Debt Issued (Repaid) | -3.37 | 1.67 | 10.26 | 14.69 | 6.15 | 4.92 | Upgrade
|
| Issuance of Common Stock | 11.39 | 11.66 | - | 0.27 | 18.63 | - | Upgrade
|
| Other Financing Activities | 0 | - | 0.01 | - | -1.2 | -0.16 | Upgrade
|
| Financing Cash Flow | 8.01 | 13.32 | 10.27 | 14.96 | 23.58 | 4.76 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | -0 | - | - | - | - | Upgrade
|
| Net Cash Flow | 10.84 | -6.95 | -7.96 | 4.21 | 3.53 | 16.27 | Upgrade
|
| Free Cash Flow | 58.32 | -19.78 | -18.53 | -10.39 | -19.76 | 8.8 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | 1717.98% | Upgrade
|
| Free Cash Flow Margin | 69.90% | -888.19% | -101.22% | -39.50% | -189.65% | 33.90% | Upgrade
|
| Free Cash Flow Per Share | 2.55 | -1.01 | -1.00 | -0.57 | -1.27 | 0.59 | Upgrade
|
| Cash Income Tax Paid | - | - | - | - | 0.05 | 0.07 | Upgrade
|
| Levered Free Cash Flow | 40.61 | -11.18 | -9.07 | -4.21 | -12.47 | 9.38 | Upgrade
|
| Unlevered Free Cash Flow | 42.44 | -9.8 | -8.21 | -3.69 | -12.3 | 9.49 | Upgrade
|
| Change in Net Working Capital | -3.87 | 0.98 | 3.06 | -0.75 | 3.23 | -8.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.